Fol. Biol. 2000, 46, 191-193
https://doi.org/10.14712/fb2000046050191
Intratumoral IL-2 Gene Transfer Improves the Therapeutic Efficacy of IL-12 but Not IL-18
References
1. , J. (1996) Cytokine gene-modified vaccines in the therapy of cancer. Pharmac. Ther. 69, 1-14.
<https://doi.org/10.1016/0163-7258(95)02016-0>
2. , J., Indrová, M., Němečková, S., Malkovský, M., von Broen, B., Pálek, V., Anderlíková, J. (1978) Solubilized tumour-associated antigens of methylcholantrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph-node cells, macrophage electrophoretic mobility assay and transplantation tests. Int. J. Cancer 21, 348-355.
<https://doi.org/10.1002/ijc.2910210316>
3. , J., Rössner, P., Bubeníková, D., Šímová, J., Indrová, M., Šloncová, E. (1997) Tumour vaccines expressing IL-2, CD80, and IL-2 plus CD80 gene. Int. J. Oncol. 11, 1213-1219.
4. , J. (2000) Interleukin 18 - interferon inducing factor - a novel player in tumour immunotherapy? Cytokine 12, 332-338.
<https://doi.org/10.1006/cyto.1999.0563>
5. , E., Klein, E. (1992) Cancer immunotherapy: are the results discouraging? can they be improved? Adv. Cancer Res. 59, 245-322.
6. , M., Saijyo, K., Hayaside, M., Yasugi, T., Kurimoto, M., Ohno, T. (1998) Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18. Jpn. J. Cancer Res. 89, 1041-1046.
<https://doi.org/10.1111/j.1349-7006.1998.tb00494.x>
7. , S., Berger, A., Zizindohoué, F., Cugnene, P. H., Thiounn, N., Fridman, W. H., Pagés, F. (2000) Interleukin 18: biological properties and clinical implications. Eur. Cytokine Netw. 11, 15-25.
8. , I., Tahara, H., Robbins, P. D., Gately, M. K., Wolf, S. F., Barnea, A., Lotze, M. T. (1995) Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J. Surg. Res. 58, 218-226.
<https://doi.org/10.1006/jsre.1995.1034>
9. , P., Bubeník, J., Indrová, M., Sobota, V., Vondrys, P., Zeuthen, J., Jandlová, T., Takáč, M. (1997) Genetically modified tumour vaccines: insertion of the IL-2 gene downregulates tumorigenicity more efficiently than insertion of the CD80 gene. Int. J. Oncol. 10, 77-82.
10. Shurin, M. R., Esche, C., Péron, J.-M., Lotze, M. T. (1997) Antitumor activities of IL-12 and mechanisms of action. In: IL-12, ed. Adorini, L., Chem. Immunol., 68, pp. 153-174, Karger, Basel.
11. , G. (1998) Interleukin 12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70, 83-243.
<https://doi.org/10.1016/S0065-2776(08)60387-9>
12. , M., Rodolfo, M., Cavallo, F., Parenza, M., Melani, C., Parmiani, G., Forni, G., Colombo, M. P. (1996) Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res. 56, 467-470.
13. , D. J. Joshi, S. S. (1995) Immune cells and cytokines: their role in cancer immunotherapy (Review). Int. J. Cancer 7, 205-223.
14. , V., Rössner, P., Indrová, M., Bubeník, J., Sobota, V. (1998) Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int. J. Cancer 76, 115-119.
<https://doi.org/10.1002/(SICI)1097-0215(19980330)76:1<115::AID-IJC18>3.0.CO;2-B>
15. , P., Šímová, J., Takáčová, S., Jandlová, T., Bubeník, J. (1997) Recombinant interleukin-2 acts as an adjuvant and helps to increase the efficacy of tumour vaccines. Folia Biol. (Praha) 43, 39-40.
16. , J. M., Komschlies, K. L., Back, T. C., Franco, J. L., Brunda, M. J., Wiltrout, R. H. (1996) Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst. 88, 38-43.
<https://doi.org/10.1093/jnci/88.1.38>
